Carbapenem-resistant Enterobacteriaceae

New menace to our antibiotic Armamentarium!

Ankita Porwal, Sevitha Bhat

Research output: Contribution to journalArticle

Abstract

Objective: To study the risk factors, clinical characteristics, and outcome in patients with infections due to CRE infections. Methods: Retrospective study was carried out in a microbiology laboratory for 6 months. 152 CRE isolates identified by the Vitek 2 compact system were included in the study. The risk factors, antibiotic treatment and clinical outcome were studied from the case sheets, Chi-square test was used for statistical analysis. Results: Of the 2520 positive cultures for Enterobacteriaceae, isolation rate of CRE was 152 (6%). 76 (50%) belonged to exudates, 22 (14.1%) blood culture, 90 (59.2%) urine. The common infection was UTI. The risk factors were prior exposure to antimicrobials, admission to intensive care unit, indwelling devices and prior hospitalization. The effective antibiotic was colistin, polymyxin B, tigecycline, cefoperazone-sulbactum, piperacillin-tazobactum. The mortality was 19.7%. Conclusion: We have demonstrated the value of understanding local epidemiology to help modify our risk-based screening as a strategy to limit the spread of CRE.

Original languageEnglish
Pages (from-to)335-338
Number of pages4
JournalAsian Journal of Pharmaceutical and Clinical Research
Volume10
Issue number9
DOIs
Publication statusPublished - 01-01-2017

Fingerprint

Carbapenems
Enterobacteriaceae
Anti-Bacterial Agents
Infection
Cefoperazone
Colistin
Polymyxin B
Piperacillin
Exudates and Transudates
Chi-Square Distribution
Microbiology
Intensive Care Units
Epidemiology
Hospitalization
Retrospective Studies
Urine
Equipment and Supplies
Mortality

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmaceutical Science
  • Pharmacology (medical)

Cite this

@article{ac0230d260a84e88b5c705372db5d37b,
title = "Carbapenem-resistant Enterobacteriaceae: New menace to our antibiotic Armamentarium!",
abstract = "Objective: To study the risk factors, clinical characteristics, and outcome in patients with infections due to CRE infections. Methods: Retrospective study was carried out in a microbiology laboratory for 6 months. 152 CRE isolates identified by the Vitek 2 compact system were included in the study. The risk factors, antibiotic treatment and clinical outcome were studied from the case sheets, Chi-square test was used for statistical analysis. Results: Of the 2520 positive cultures for Enterobacteriaceae, isolation rate of CRE was 152 (6{\%}). 76 (50{\%}) belonged to exudates, 22 (14.1{\%}) blood culture, 90 (59.2{\%}) urine. The common infection was UTI. The risk factors were prior exposure to antimicrobials, admission to intensive care unit, indwelling devices and prior hospitalization. The effective antibiotic was colistin, polymyxin B, tigecycline, cefoperazone-sulbactum, piperacillin-tazobactum. The mortality was 19.7{\%}. Conclusion: We have demonstrated the value of understanding local epidemiology to help modify our risk-based screening as a strategy to limit the spread of CRE.",
author = "Ankita Porwal and Sevitha Bhat",
year = "2017",
month = "1",
day = "1",
doi = "10.22159/ajpcr.2017.v10i9.19448",
language = "English",
volume = "10",
pages = "335--338",
journal = "Asian Journal of Pharmaceutical and Clinical Research",
issn = "0974-2441",
publisher = "Innovare Academics Sciences Pvt. Ltd",
number = "9",

}

Carbapenem-resistant Enterobacteriaceae : New menace to our antibiotic Armamentarium! / Porwal, Ankita; Bhat, Sevitha.

In: Asian Journal of Pharmaceutical and Clinical Research, Vol. 10, No. 9, 01.01.2017, p. 335-338.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Carbapenem-resistant Enterobacteriaceae

T2 - New menace to our antibiotic Armamentarium!

AU - Porwal, Ankita

AU - Bhat, Sevitha

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Objective: To study the risk factors, clinical characteristics, and outcome in patients with infections due to CRE infections. Methods: Retrospective study was carried out in a microbiology laboratory for 6 months. 152 CRE isolates identified by the Vitek 2 compact system were included in the study. The risk factors, antibiotic treatment and clinical outcome were studied from the case sheets, Chi-square test was used for statistical analysis. Results: Of the 2520 positive cultures for Enterobacteriaceae, isolation rate of CRE was 152 (6%). 76 (50%) belonged to exudates, 22 (14.1%) blood culture, 90 (59.2%) urine. The common infection was UTI. The risk factors were prior exposure to antimicrobials, admission to intensive care unit, indwelling devices and prior hospitalization. The effective antibiotic was colistin, polymyxin B, tigecycline, cefoperazone-sulbactum, piperacillin-tazobactum. The mortality was 19.7%. Conclusion: We have demonstrated the value of understanding local epidemiology to help modify our risk-based screening as a strategy to limit the spread of CRE.

AB - Objective: To study the risk factors, clinical characteristics, and outcome in patients with infections due to CRE infections. Methods: Retrospective study was carried out in a microbiology laboratory for 6 months. 152 CRE isolates identified by the Vitek 2 compact system were included in the study. The risk factors, antibiotic treatment and clinical outcome were studied from the case sheets, Chi-square test was used for statistical analysis. Results: Of the 2520 positive cultures for Enterobacteriaceae, isolation rate of CRE was 152 (6%). 76 (50%) belonged to exudates, 22 (14.1%) blood culture, 90 (59.2%) urine. The common infection was UTI. The risk factors were prior exposure to antimicrobials, admission to intensive care unit, indwelling devices and prior hospitalization. The effective antibiotic was colistin, polymyxin B, tigecycline, cefoperazone-sulbactum, piperacillin-tazobactum. The mortality was 19.7%. Conclusion: We have demonstrated the value of understanding local epidemiology to help modify our risk-based screening as a strategy to limit the spread of CRE.

UR - http://www.scopus.com/inward/record.url?scp=85029605746&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85029605746&partnerID=8YFLogxK

U2 - 10.22159/ajpcr.2017.v10i9.19448

DO - 10.22159/ajpcr.2017.v10i9.19448

M3 - Article

VL - 10

SP - 335

EP - 338

JO - Asian Journal of Pharmaceutical and Clinical Research

JF - Asian Journal of Pharmaceutical and Clinical Research

SN - 0974-2441

IS - 9

ER -